Chain Bridge I to Acquire Phytanix Bio, Creating a New Public Company Focused on Developing Next Generation Cannabinoid and Cannabinoid-like Medicines
Phytanix Bio and Chain Bridge I Merger: Phytanix Bio, a preclinical pharmaceutical company focused on cannabinoid-based medicines, has announced a merger with Chain Bridge I (CBRG), valuing the combined entity at approximately $58 million, with plans to list on Nasdaq under the ticker "PHYX" by Q4 2024.
Leadership and Drug Development Focus: The new company will be led by experienced executives from Phytanix Bio, aiming to advance innovative cannabinoid therapies for conditions like treatment-resistant facial seizures and Painful Bladder Syndrome, leveraging their extensive expertise in drug development and intellectual property.
Trade with 70% Backtested Accuracy
Analyst Views on CBRG
No data
About CBRG
About the author
Chain Bridge I to Acquire Phytanix Bio, Creating a New Public Company Focused on Developing Next Generation Cannabinoid and Cannabinoid-like Medicines
Phytanix Bio and Chain Bridge I Merger: Phytanix Bio, a preclinical pharmaceutical company focused on cannabinoid-based medicines, has announced a merger with Chain Bridge I (CBRG), valuing the combined entity at approximately $58 million, with plans to list on Nasdaq under the ticker "PHYX" by Q4 2024.
Leadership and Drug Development Focus: The new company will be led by experienced executives from Phytanix Bio, aiming to advance innovative cannabinoid therapies for conditions like treatment-resistant facial seizures and Painful Bladder Syndrome, leveraging their extensive expertise in drug development and intellectual property.
Chain Bridge I to buy Phytanix Bio
Business Combination Announcement: Phytanix Bio and Chain Bridge I have entered into a definitive agreement for a business combination, expected to close in Q4 2024, with Phytanix anticipated to receive up to $11M in cash from CBRG's trust.
Leadership and Future Plans: The combined entity will be named Phytanix, listed on Nasdaq under the ticker “PHYX,” and will be led by Phytanix Bio’s founders, with Barrett Evans serving as CEO.
Chain Bridge I to Acquire Phytanix Bio, Creating a New Public Company Focused on Developing Next Generation Cannabinoid and Cannabinoid-like Medicines
Phytanix Bio and Chain Bridge I Merger: Phytanix Bio, a preclinical pharmaceutical company focused on cannabinoid-based medicines, has announced a merger with Chain Bridge I (CBRG), valuing the combined entity at approximately $58 million, with plans to list on Nasdaq under the ticker "PHYX" by Q4 2024.
Leadership and Drug Development Focus: The new company will be led by experienced executives from Phytanix Bio, aiming to advance innovative cannabinoid therapies for conditions like treatment-resistant facial seizures and Painful Bladder Syndrome, leveraging their extensive expertise in drug development and intellectual property.
Chain Bridge I to buy Phytanix Bio
Business Combination Announcement: Phytanix Bio and Chain Bridge I have entered into a definitive agreement for a business combination, expected to close in Q4 2024, with Phytanix anticipated to receive up to $11M in cash from CBRG's trust.
Leadership and Future Plans: The combined entity will be named Phytanix, listed on Nasdaq under the ticker “PHYX,” and will be led by Phytanix Bio’s founders, with Barrett Evans serving as CEO.
